Pan Yihang, Wang Xueke, Liu Xiwang, Shen Lihua, Chen Qixing, Shu Qiang
Department of Clinical Research Center, The Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Department of Thoracic & Cardiovascular Surgery, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Antioxidants (Basel). 2022 Nov 6;11(11):2196. doi: 10.3390/antiox11112196.
Ischemia-reperfusion (I/R) injury is a major challenge in perioperative medicine that contributes to pathological damage in various conditions, including ischemic stroke, myocardial infarction, acute lung injury, liver transplantation, acute kidney injury and hemorrhagic shock. I/R damage is often irreversible, and current treatments for I/R injury are limited. Ferroptosis, a type of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides, has been implicated in multiple diseases, including I/R injury. Emerging evidence suggests that ferroptosis can serve as a therapeutic target to alleviate I/R injury, and pharmacological strategies targeting ferroptosis have been developed in I/R models. Here, we systematically summarize recent advances in research on ferroptosis in I/R injury and provide a comprehensive analysis of ferroptosis-regulated genes investigated in the context of I/R, as well as the therapeutic applications of ferroptosis regulators, to provide insights into developing therapeutic strategies for this devastating disease.
缺血再灌注（I/R）损伤是围手术期医学面临的一项重大挑战，它在多种病症中都会导致病理损伤，包括缺血性中风、心肌梗死、急性肺损伤、肝移植、急性肾损伤和失血性休克。I/R损伤通常是不可逆的，目前针对I/R损伤的治疗方法有限。铁死亡是一种受调控的细胞死亡类型，其特征是脂质氢过氧化物的铁依赖性积累，已被认为与多种疾病有关，包括I/R损伤。新出现的证据表明，铁死亡可作为减轻I/R损伤的治疗靶点，并且已经在I/R模型中开发了针对铁死亡的药理学策略。在此，我们系统地总结了I/R损伤中铁死亡研究的最新进展，并对在I/R背景下研究的铁死亡调节基因以及铁死亡调节剂的治疗应用进行了全面分析，以便为开发针对这种毁灭性疾病的治疗策略提供见解。
